Roche makes its next move in antibiotic research with its licensing deal with Meiji Seika Pharma and Canada’s Fedora. The deal, worth up to $750 million, allows Roche the right to develop and commercialize beta-lactamase inhibitor OP0595 internationally, with exception to Japan. Meiji gets to keep its sole rights.
Beta-lactamase inhibitors restore or potentiate the activity of beta-lactam antibiotics. The combination of OP0595 with a beta-lactam antibiotic targets severe infections caused by Enterobacteriaceae, including multi-drug-resistant strains.
“There is an urgent need for new antibiotics able to combat the increasing resistance to antibiotics that is being seen worldwide,” said Janet Hammond, Head of Infectious Diseases for Roche Pharma Research and Early Development (pRED). “Roche has a strong legacy in antibiotics and this collaboration demonstrates we are continuing to execute on our commitment. This beta-lactamase inhibitor has the potential for an expanded spectrum against multi-drug resistant bacteria and could be a much needed option for patients suffering from difficult-to-treat infections.”
Under this agreement, Meiji and Fedora will be receive upfront, development regulatory and sales event milestone payments summing up potentially to $750 million. Furthermore, Meiji and Fedora will receive entitled royality on sales of products originated from this collaboration.
For more information, please refer to Roche’s press release over here.
That’s two big news on antibiotics, including the $102/share Merck and Cubist acquisition deal. The battle of the superbugs continues.
What are your thoughts on this matter? Will we be expecting another pharma to take another slice of this pie?